Search
Results for “CGRP”
Articles
-
Triptans Enhance Anti-CGRP Treatment Response
New study reveals migraine patients using triptans show 55% better response to anti-CGRP treatments. 336-patient analysis explains why combination therapy works.
-
How to Manage CGRP Injection Site Reactions
Learn how to manage CGRP injection site reactions with proven tolerance protocols. Complete guide for patients experiencing skin reactions to Aimovig, Ajovy, Emgality with step-by-step treatment...
-
CGRP Therapy Medications List
Compare CGRP migraine medications with our comprehensive list detailing receptor/ligand targets, dosages, and whether they're preventive or abortive treatments for effective migraine management.
-
Clinical Features VS Anti-CGRP Treatment Response
How will I respond to anti-cgrp monoclonal antibodies?
-
CGRP Monoclonal Antibody (mAb) Adverse Events Chart
Comprehensive guide to CGRP monoclonal antibody side effects (Aimovig, Ajovy, Emgality, Vyepti). Real-world data from 65,000+ patients. Know what to expect from your injectable migraine prevention...
-
CGRP and Migraine: The Molecule and the New Drugs
CGRP is the molecule behind the newest migraine drugs. What CGRP is, how it triggers an attack, and how anti-CGRP antibodies and gepants prevent or stop...
-
The Promise and Challenges of CGRP as a Migraine Biomarker
While diagnosis and treatment monitoring of migraine disease largely rely on patient-reported symptoms, the discovery of calcitonin gene-related peptide (CGRP) as a potential biomarker has sparked...
-
New Safety Insights from CGRP Antibody Study
New study of 14,285 patients reveals CGRP antibodies (Aimovig, Ajovy, Emgality, Vyepti) remain safe for migraine prevention. Researchers identified 15 potential safety signals, including palpitations and...
-
Migraine Attacks Independent of CGRP (cGMP-mediated migraine)
A randomized, double-blind, placebo-controlled study published in Cephalalgia investigated whether sildenafil (Viagra), a phosphodiesterase-5 (PDE-5) inhibitor that increases cGMP levels, could induce migraine attacks in individuals with migraine...
-
Long-Term Safety of Anti-CGRP Monoclonal Antibodies
A comprehensive meta-analysis of over 4,300 patients reveals that erenumab, galcanezumab, fremanezumab, and eptinezumab maintain good tolerability beyond 12 months. Only 3% of patients stopped treatment...
-
Will I Respond Again To Anti-CGRP Monoclonal Antibody Therapy After Discontinuation?
Will I Respond Again To Anti-CGRP Monoclonal Antibody Therapy?
-
Groundbreaking study!: Anti-CGRP Monoclonal Antibodies Disease-Modifying!?
Exciting new research reveals that long-term treatment with anti-CGRP antibodies may do more than just manage migraine symptoms - it could actually change the course of...
-
CGRP Migraine Drugs and Blood Pressure: What to Know
A new meta-analysis of 19 randomized trials weighs whether CGRP migraine preventives like erenumab raise blood pressure, and what it means for monitoring.
-
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Migraine Treatment
The researchers discovered that 3.1% of participants experienced abnormal ECGs or cardiovascular adverse events. Among these, 1.6% encountered more severe complications, such as cerebellar stroke, spontaneous...
-
Do Anti-CGRP mAbs Work For Aura In Migraine With Aura Patients?
Do anti-CGRP monoclonal antibodies reduce migraine aura? Why they may not act on aura directly, and what studies show for migraine with aura.
-
Can a Blood Test Measure Your Migraine? What a Large CGRP Study Found
A large Neurology study measured plasma CGRP in 588 people with migraine and found levels were lower than in healthy controls, not higher, and did not...
-
Anti-CGRP Monoclonal Antibody Migraine Treatment: Super-Responders and Absolute Responders and When to Expect Results
Anti-CGRP monoclonal antibodies achieved 70% super-response and 23% complete migraine freedom in a one-year study. Most dramatic improvements occurred after 6 months of treatment. For patients...
-
What is the optimal duration of treatment with anti-CGRP mAbs to determine their efficacy for each individual patient?
What is the optimal duration of treatment with anti-CGRP mAbs to determine their efficacy for each individual patient?
-
Answers to Key Questions for Peter Goadsby, MD, PhD, FRS on the Topic of Migraine Biochemistry: CGRP & Beyond (Migraine World Summit - Day 2)
Key Questions for Peter Goadsby, MD, PhD, FRS on the Topic of Migraine Biochemistry: CGRP & Beyond (Migraine World Summit - Day 2)
-
A quick summary of what we currently know about PACAP in terms of migraine treatment
If you are new migraine research in general, you may not have heard of it, but it does play a significant role in migraine pathophysiology. Think of...
-
Rimegepant for Migraine Prevention: Real-World Evidence
New real-world data on rimegepant for migraine prevention: a 75 mg every-other-day gepant that also treats attacks. What the GEMA study found on response rates, dosing,...
-
A Breakthrough on the Horizon: PACAP-Targeting Antibodies Offer New Promise for Migraine Prevention
Migraine patients may soon have a new treatment option. Recent clinical trials show promising results for Lu AG09222, a monoclonal antibody targeting PACAP, a neuropeptide involved...
-
The Hidden Link Between Acne and Migraine
New 2025 study reveals adults with acne have 65% higher migraine risk. Discover the CGRP connection and treatment options for both conditions.
Pages
-
Migraine Resource Hub
The Cerebral Torque Migraine Resource Hub: evidence-based guides on migraine science, subtypes, acute and preventive treatment, and new research.
